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Abstract: Many patients, especially those with a high pill burden and multiple chronic illnesses, are
less adherent to medication. In medication treatments utilizing polypills, this problem might be
diminished since multiple drugs are fused into one formulation and, therefore, the therapy regimen is
simplified. This systematic review summarized evidence to assess the effect of polypills on medication
adherence. The following databases were searched for articles published between 1 January 2000,
and 14 May 2019: PubMed, Web of Science, Cochrane Library, and Scopus. Medication adherence
was the only outcome assessed, regardless of the method of measuring it. Sixty-seven original
peer-reviewed articles were selected. Adherence to polypill regimens was significantly higher in
56 articles (84%) compared to multiple pill regimens. This finding was also supported by the results
of 13 out of 17 selected previously published systematic reviews and meta-analyses dealing with this
topic. Adherence can be improved through the formulation of polypills, which is probably why the
interest in researching them is growing. There are many polypills on the market, but the adherence
studies so far focused mainly on a small range of medical conditions.
Keywords: polypill; fixed-dose combination; adherence; systematic review
1. Introduction
Poor medication adherence is a widespread and unresolved challenge among patients [1]. Only half
of the prescribed doses are taken, and many patients stop their treatment before the planned end of the
therapy [1–3]. Several factors contribute to low adherence rates, such as ineffective communication
between the patient and the physician, or patients perceive their treatment as unnecessary. Patients
may also think the benefits of their pharmacotherapy do not outweigh its adverse effects, or they simply
forget [4]. This very often results in complications, extra healthcare costs, side effects, and therapeutic
failures. Therefore, improving adherence is a crucial factor in increasing the likelihood of positive
therapeutic outcomes.
Patients with chronic illnesses must quite often take multiple pills every day for months or even
years, which will eventually result in less adherence to their medication [5]. This occurs especially in
cardiovascular diseases (CVD), where patients do not feel the symptoms of their disease in the short
term, and it is easier for them to forget to take their medicines [6]. The same goes for diabetes patients;
in mild forms, diabetes does not cause serious complications, and patients do not feel ill; thus, they
tend to forget their medication [7].
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Polypills are a technological innovation that is expected to improve adherence by simplifying
the pharmacotherapy regimen [2,5]. The concept of the polypill, very often referred to as a fixed-dose
combination (FDC), is quite simple. Instead of taking two or more pills (each containing one active
ingredient), multiple drugs are combined into one formulation [6,8,9]. It is generally thought that
taking fewer pills will lead to better adherence [2]. This systematic review examines the evidence for
that idea and assesses the evidence of the effects of a reduced pill burden on medication adherence.
2. Materials and Methods
2.1. Search Strategy
This systematic review is focused on articles concerning fixed-dose combinations (FDCs), also
known as polypills, in comparison to their separate drug formulations (multiple tablets, free-pill
combinations). It does not matter how many drugs are combined in a certain formulation.
The method followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [10]. The search was done in May 2019, and it covered the following databases:
PubMed, Web of Science, Cochrane Library, and Scopus. After screening all titles and articles,
the reference lists of selected articles were used to identify additional relevant studies.
In all four databases, the following selection of keywords was applied: (compliance OR adherence
OR non-compliance OR non-adherence OR noncompliance OR nonadherence) AND ((fixed NEAR/1
combination*) OR single-pill* OR single-tablet* OR polypill* OR “combination pill*”). The principle
behind this selection was to make an extensive search that would cover only the relevant articles
by using as many synonyms and antonyms for two terms related to the aim of our study: polypills
and adherence. The search included a language filter, which showed only articles written in English.
Furthermore, a time-span filter was used, which included only articles published since 1 January 2000.
2.2. Inclusion and Exclusion Criteria
Articles were included in the systematic review if they were either original peer-reviewed studies
or systematic reviews and meta-analyses. Narrative reviews and conference abstracts were excluded.
There were no restrictions concerning the type of patients, diseases, comorbidities, or drugs. Adherence
was the only essential outcome measure for an article to be considered, regardless of how it was
measured. Other outcomes were not assessed. All articles needed to have a comparison between
low and high pill burden groups, meaning that one group had to take more pills than another group.
This was possible either with control groups (longitudinal, controlled) or when observing one group
with patients who changed their pill burden over time (longitudinal, uncontrolled). It was also
necessary that the articles dealt with solid dosage formulations rather than with any other dosage form.
Additionally, articles dealing with persistence instead of adherence were excluded. The definitions
of these two terms are vague since they stand for a similar phenomenon and, thus, they tend to overlap
in different literature. However, for this study, only articles measuring adherence were included,
and the ones that clearly stated that they dealt only with persistence were excluded.
2.3. Study Selection and Data Extraction
Both researchers (A.B. and K.D.) searched for the articles separately to make the most credible
and objective article selection. Their findings were then compared, and discussions were held until
a final decision about included articles was reached.
Key information about all relevant studies was extracted from the articles. For original
peer-reviewed studies, the extracted information included author of the study, year of publication,
study country, design, setting, aim and population, disease in question, follow-up period, adherence
measures, main outcomes, number and international nonproprietary names (INN) of active ingredients
used in the study, and their dosage (if given). For systematic reviews and meta-analyses, the extracted
data covered the author of the study, year of publication, medical condition in focus, study aim, number
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of included original studies, and main results. For further working progress, articles were grouped by
(i) article type, that is, original studies separately from systematic reviews and meta-analyses, and (ii)
the type of disease they were dealing with.
2.4. Quality Assessment
Quality assessment of the included studies was systematically done using Cochrane Collaboration’s
risk of bias assessment tool for randomized controlled trials [11] and the Newcastle–Ottawa scale
for cohort studies [12]. As adherence was the only outcome of interest, assessment of how any other
outcomes were dealt with was ignored.
Cochrane Collaboration’s risk of bias tool measures risk of bias in randomized controlled trials
through seven domains: sequence generation and allocation concealment (selection bias), blinding of
participants (performance bias), blinding of outcome assessment (detection bias), incomplete outcome
data (attrition bias), selective reporting (reporting bias), and other bias. Each domain is assessed as
having high, low, or unclear risk of bias. Studies with low risk of bias for all criteria were considered
to be of low risk, studies with low or unclear risk of bias were considered medium risk, and studies
with at least one domain assessed as high risk of bias were considered as having an overall high risk
of bias [11]. However, as all randomized controlled trials were inherently open-label, meaning that
blinding of participants was impossible due to the nature of the intervention, this domain was always
assessed as having a high risk of bias and, therefore, omitted from the overall evaluation of studies.
The Newcastle-Ottawa scale was used for observational studies; it measures quality through three
main domains: selection, comparability, and outcome. Each study was awarded a maximum of nine
stars, depending on whether it reached certain standards within these domains (maximum four stars
for selection, two stars for comparability, and three stars for outcome) [12]. Studies with 0–4 stars
were considered as low quality, studies with 5–7 stars were considered as medium quality, and studies
having eight or nine stars were considered as high quality.
3. Results
The database search yielded 5170 records, of which 2287 were screened after removal of duplicates
and inclusion of time-span and language filters. After the inclusion and exclusion criteria were applied
to screen the records, 84 articles were included in our systematic review; 67 of them were original
peer-reviewed studies and 17 were systematic reviews and/or meta-analyses. For the flow chart of the
article selection process, see Figure 1.
3.1. Included Systematic Reviews and Meta-Analyses (n = 17)
After the selection process of eligible studies, 17 systematic reviews and/or meta-analyses out of 136
articles were included in this systematic review (Figure 1, Table A1, Appendix A). Of these studies, eight
were meta-analyses (47%) [13–20], two were systematic reviews (12%) [21,22], and seven were defined
as a systematic review with meta-analysis (41%) [23–29]. The most common systematically reviewed
medical condition was hypertension (n = 5, 29%) [14–16,25,26], followed by studies dealing with CVDs
in general (n = 3, 18%) [17,18,21], human immunodeficiency virus (HIV) (n = 4, 24%) [19,20,24,27],
diabetes (n = 2, 12%) [22,28], and tuberculosis (n = 1, 6%) [23] (Table 1). Two studies examined the
effect of polypills in several medical conditions [13,29]. Thirteen of the selected articles (76%) favored
therapy with FDC over separate-pill therapy regimens [13–16,18–22,24,25,27,28].
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Table 1. Summary of conclusions per disease in previously published systematic reviews and
meta-analyses (n = 17).
Disease Conclusions Concerning
Adherence to FDCT
Study Design [Reference]
Meta-Analysis Systematic Reviewwith Meta-Analysis
Systematic
Review
Various diseases (n = 2)
FDCT > MPT (n = 1) [13]
Inconclusive (n = 1) [29]
Hypertension (n = 5)
FDCT > MPT (n = 4) [14–16] [25]
Inconclusive (n = 1) [26]
CVD (n = 3)
FDCT > MPT (n = 2) [18] [21]
FDCT = MPT (n = 1) [17]
HIV (n = 4) FDCT > MPT (n = 4) [19,20] [24,27]
Diabetes (n = 2) FDCT > MPT (n = 2) [28] [22]
Tuberculosis (n = 1) FDCT not favored (n = 1) [23]
FDCT, fixed-dose combination therapy; MPT, multipill therapy; CVD, cardiovascular disease; HIV, human
immunodeficiency virus.
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However, some overlap of the articles that these studies investigated was found. For example,
Selak et al. [17] and Webster et al. [18] included the same studies, which were also included by
Bahiru et al. [21] Furthermore, there is much overlap between studies conducted by Gupta et al. [16],
Kawalec et al. [25], Sherrill et al. [15], and Du et al. [14]. Both studies conducted by Clay et al. [20,24]
share some of the included articles as well. For a visual representation of the overlap of the studies
included in the abovementioned systematic reviews and meta-analyses, please see Figure 2.
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Figure 2. Visual representation of the overlap of the studies included in other systematic reviews and
meta-analyses (SR and MA; n = 17). One row represents one SR/MA. Each colored square symbolizes
one article, and the number of colored squares is equal to the number of studies included in the
corresponding SR/MA. Different colors represent into how many SRs/MAs an article was included (e.g.,
if all the colored squares in a row are blue, all the articles are unique to only this SR/MA). Blue: study
included only in one SR/MA. Red: study included in two different SRs/MAs. Yellow: study included in
three different SRs/MAs. Green: study included in four different SRs/MAs. Purple: study included in
five different SRs/MAs.
Some of the studies investigated in one or more of the previously published systematic reviews and
meta-analyses were also included in our systematic review since they fit the inclusion criteria [5,30–57].
3.2. Included Original Peer-Reviewed Studies (n = 67)
Altogether, 67 original peer-reviewed studies out of a total of 5170 articles met the inclusion criteria
and were included in our study (Figure 1). Of the 67 articles, 31 (46%) were related to hypertension (HT),
14 (21%) were related to human immunodeficiency virus (HIV), 11 (16%) were related to cardiovascular
disease (CVD), 10 (15%) were related to diabetes mellitus type II (DMII), and one dealt with lower
urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BHP). Studies were
conducted in different countries worldwide; some of them even included more than one country. Most
of them (n = 36) were conducted in the United States, and only one was carried out in South America,
in two different countries. More details can be found in Table 2.
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Table 2. General information about reviewed articles (n = 67).
Information of
Interest
Result (Number of Studies with
a Certain Feature) References
Disease
CVD (n = 11) [35,45,48,49,52,58–63]
HT (n = 31) [5,33,38–42,46,53,55,56,64–83]
DMII (n = 10) [31,32,36,43,44,51,54,84–86]
HIV (n = 14) [30,34,37,47,50,57,87–94]
LUTS/BHP (n = 1) [95]
Country where
the study was
conducted (in
alphabetical
order)
Argentina (n = 1) [35]
Australia (n = 3) [45,58,61]
Austria (n = 1) [66]
Belgium (n = 2) [66,88]
France (n = 1) [59]
Germany (n = 4) [7,66,67,79]
Greece (n = 1) [85]
India (n = 1) [52]
Ireland (n = 1) [52]
Italy (n = 8) [35,40,42,69,70,84,87,92]
Japan (n = 2) [73,75]
Korea (n = 1) [64]
The Netherlands (n = 5) [52,59,66,88,95]
New Zealand (n = 1) [48]
Paraguay (n = 1) [35]
Romania (n = 1) [77]
Spain (n = 2) [35,90]
Switzerland (n = 1) [66]
Taiwan (n = 5) [5,53,71,78,80]
UK (n = 1) [52]
USA (n = 36) [30–34,36–39,41,43,44,46,49–51,54–57,60,62,63,65,68,72,74,76,81–83,86,89,91,93,94]
Follow-up
period (given
as the exact,
average, or
minimal value,
depending on
the study)
6 weeks (n = 1) [91]
2 months (n = 4) [37,57,89,93]
3 months (n = 1) [73]
18 weeks (n = 1) [59]
24 weeks (n = 1) [85]
6 months (n = 16) [30,32,42–44,46,51,54,55,58,66,68,70,72,75,87]
9 months (n = 1) [35]
12 months (n = 26) [31,33,36,38–41,48,49,52,56,60,62,64,65,67,71,74,76,80–84,86,95]
15 months (n = 1) [78]
18 months (n = 3) [34,45,50]
1.7 years (n = 1) [94]
96 weeks (n = 1) [90]
24 months (n = 5) [5,53,61,69,88]
33 months (n = 1) [47]
36 months (n = 1) [63]
4 years (n = 1) [77]
5 years (n = 2) [79,92]
Year of
publication
2002–2004 (n = 3) [32,43,49]
2005–2007 (n = 4) [40,54,60,89]
2008–2010 (n = 15) [30,33,36,38,39,41,44,46,51,55,56,62,68,72,87]
2011–2013 (n = 10) [31,34,37,52,63,65,73,75,83,84]
2014–2016 (n = 22) [5,35,42,45,47,48,50,57–59,66,70,76,78,80–82,85,86,88,91,93]
2017–2019 (n = 13) [14,53,61,64,69,71,74,77,79,90,92,94,95]
Study design
Randomized clinical study (n = 7) [35,45,48,52,59,75,88]
Retrospective cohort study (n = 52) [5,31–33,36–44,46,47,49–51,53–58,60–65,67–72,74,76–84,86,89,92–95]
Prospective cohort study (n = 8) [30,34,66,73,85,87,90,91]
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Table 2. Cont.
Information of
Interest
Result (Number of Studies with
a Certain Feature) References
Number of
drugs in the
polypill
examined in
the study
Two drugs (n = 41) [5,31–33,36,38–44,46,49,51,53–56,58,60–65,67–73,75,78–80,83,85,89,95]
Three drugs (n = 11) [30,34,35,37,47,50,66,81,82,87,88]
Four drugs (n = 5) [45,48,52,59,90]
Five drugs (n = 1) [57]
Not mentioned (n = 9) [74,76,77,84,86,91–94]
CVD, cardiovascular disease; DMII, diabetes mellitus type 2; LUTS/BHP, lower urinary tract symptoms associated
with benign prostatic hyperplasia; HT, hypertension; HIV, human immunodeficiency virus; UK, United Kingdom;
USA, United States of America.
A summary of these 67 studies can be found in Table A2 (Appendix B), displaying author, year of
publication, country of the study, study design, study aim, study setting and follow-up period, study
population, outcome measures, and results.
Most of the studies (n = 41; 61%) examined the effects of treatment with polypills, where only two
drugs were combined (see Tables 2 and 3). However, in HIV therapy, the use of three-drug formulations
was dominant over any other (seven out of 14 studies). There were no data on combining more than
five drugs into one formulation. Additional information about the combinations of active ingredients
in polypills can be found in Table A3 (Appendix C).
Table 3. Visualization of number of active ingredients contained in a polypill. Written in the table
are numbers of the studies with the given characteristics (disease and number of active ingredients in
the polypill).
Disease Number of Studies Dealing with a PolypillContaining a Given Number of Active Ingredients (2, 3, 4, 5, or Not Mentioned)
II III IV V Not mentioned
CVD 6 [49,58,60–63] 1 [35] 4 [45,48,52,59] 0 0
HT
25
[5,33,38–42,46,53,56,64,
65,67–73,75,78–80,83,94]
3 [66,81,82] 0 0 3 [74,76,77]
DMII 8[31,32,36,43,44,51,54,85] 0 0 0 2 [84,86]
HIV 1 [89] 7 [30,34,37,47,50,87,88] 1 [90] 1 [57] 4 [91–94]
LUTS/BPH 1 [95] 0 0 0
Sum 41 11 5 1 9
CVD, cardiovascular disease; DMII, diabetes mellitus type 2; LUTS/BHP, lower urinary tract symptoms associated
with benign prostatic hyperplasia; HT, hypertension; HIV, human immunodeficiency virus.
3.3. Adherence Measures Used in the Studies (n = 67)
Table 4 summarizes methods for measuring adherence that were used in the selected articles (n= 67).
Most of the studies (n = 62; 93%) relied only on one method; however, five studies [35,50,59,79,82]
combined two different methods to assess medication adherence. The applied methods could be
divided into two broad categories: subjective (e.g., patient interviews and self-reporting) and indirect
(e.g., pill counts, methods using prescription fills, electronic monitoring) [75]. Some of the methods are
more general and applicable to more cases, whereas some were used only in a specific study. The most
commonly used measure was medical possession ratio (MPR; n = 30, 45%), followed by proportion of
days covered (PDC; n = 21, 31%).
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Table 4. Methods for measuring adherence applied in the articles (n = 67).
Method Study-Specific/General Short Description Assessment of Level of Adherence
n of Studies
[References]
Medication possession
ratio (MPR) General
Uses pharmacy prescription claims calculated
as the number of days’ supply divided by the
number of days between the first refill and the
end of the follow-up period
Low adherence: MPR < 0.5
Intermediate adherence: MPR = 0.5–0.8
High adherence: MPR > 0.8
n = 30
[5,31–33,36,39–41,43,
44,49–51,54,55,57,58,
60,62–64,67,80,82,84,
86,89,91,94,95]
Proportion of days
covered (PDC) General
Uses prescription claims data; every day has to
be covered by the medication; coverage is
calculated based on the refill data.
For example, if the patient has 30 pills in his
prescription (1/day) and he gets a refill after
40 days, his PDC is 30/40 or 75%.
A PDC of >80% is considered adherent.
n = 21
[38,42,46,53,56,61,65,
68–72,74,76,78,79,81–
83,90,93]
Pill count General
Healthcare professional pays an unexpected
visit to the patient’s home and counts the pills
left; difference between the number of pills
dispensed and the number of pills not taken
gets divided by number of prescribed pills.
Patient is considered adherent, if the
percentage is between 80% and 110%.
n = 6
[30,35,47,73,75,91]
Morisky scale General Questionnaire containing eight questions;a self-assessment scale. Based on the sum of the scores.
n = 3
[35,59,66]
Self-reporting Study-specific
1. Asking the patients about the names and
dosages of all drugs that are currently
taken [48].
2. Self-reported use of indicated combination
treatment (antiplatelet, statin, and ≥2
blood-pressure-lowering therapies for ≥4 of
the previous seven days) [45,52].
3. Self-reporting of missed doses at each
medical visit [50].
4. Completing a compliance
questionnaire—nine questions about the
names and dosages of all drugs, missing doses,
treatment interruptions, etc. [85]
1. Adherent: patients reported taking
an antiplatelet, statin, and two or more
blood-pressure-lowering drugs.
Non-adherent: patients who forgot one or
more drugs.
2. Level of adherence not assessed.
3. It was assumed that each day of ART missed
was an additional
day between refills of a 30-day supply→MPR
method was applied.
4. Adherent: not missing any drug dose or no
more than 2 doses per week, received the
correct dosage of the medication, and not
interrupting their treatment.
n = 5
[45,48,50,52,85]
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Table 4. Cont.
Method Study-Specific/General Short Description Assessment of Level of Adherence
n of Studies
[References]
Visual Analog Scale
(VAS) General
Uses information given by the patient who
performs self-assessment of adherence on
a scale 0–100.
Non-adherent: 0
Perfectly adherent: 100 n = 2 [34,87]
Simplified Medication
Adherence
Questionnaire (SMAQ)
General Self-reported questionnaire focused on HIVpatients, containing six items.
Method of assessment is not given in
the article. n = 1 [88]
Prescription records
review Study-specific
Computing the total number of consecutive
months that was covered by antihypertensive
prescriptions during the study; adherence is
expressed as percentage of time.
Low adherence: <20%
Medium adherence: 20–79%
High adherence: ≥80%
n = 1 [77]
Electric adherence
monitoring
General principle,
study-specific
design (depends
on the dosage
form, dosage
regimen, etc.)
The medication vial was closed with a cap
containing a microprocessor, which was
recording date and time of all openings.
The vial was filled with the exact amount of
medication required for the complete
treatment period. The participant was
instructed not to open the vial except when
taking the medication according to the
prescribed regimen.
Based on whether the patient was taking the
doses daily and according to the schedule. n = 1 [59]
Time to the first instance
to discontinuation *
General method,
study-specific
definition
Defined as no repeat of prescription within
150% of the previous days’ supply.
Treatment discontinuation: break of therapy
for more than 150% of the previous
days’ supply.
n = 1 [79]
RDD/PDD ratio General
Ratio between received daily dose
(corresponds to
the ratio between total doses received and
treatment days) and prescribed daily dose
(stands for the intention to treat and the real
prescriptive tendency).
Adherence is assessed and given only as
an RDD/PDD ratio; there is no evaluation of
what is considered high or low adherence.
n = 1 [92]
* Usually used as a measure of therapy persistence. ART, antiretroviral therapy; RDD, received daily dose; PDD, prescribed daily dose.
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3.4. Adherence Outcome
All studies had one or more groups that received more pills than their control groups (Table A2,
Appendix B). Those groups could be either a cohort of the same group or a comparison between
two different groups. In most cases, the control group was a group of patients on the usual therapy
(multiple pills). The test subjects received exactly the same active ingredients as the control group, but
in a single formulation [31–33,35,41–43,54,59,61,67,69,70,73,81,85,89]; alternatively, the test group and
the control group were not necessarily receiving the same drugs, but they simply had a different pill
burden [5,30,34,36–40,44–53,55–58,60,62,64–66,68,71,72,74–80,82–84,86–88,90–95].
The main interest of this review is how the pill burden is associated with patient adherence. In 56
out of 67 studies (84%), there was a significant difference in adherence between the test and control
group (Table 5). In seven studies (10%), the difference between both groups was insignificant. In only
two studies (3%), both opposite outcomes (improved and decreased adherence in the test group,
depending on the treatment situation before the study index date) were reported [61,80]. See Table 5
for a summary of the outcomes.
Table 5. Summary of the study results per disease. Statistically significant differences in adherence
outcomes are presented and considered.
Disease
Comparison of Adherence Outcome between
FDCT and MPT; Number of Studies with
Certain Result Is Given in Parenthesis
References
CVD
(n = 11)
FDCT > MPT (n = 9) [35,45,48,49,52,59,60,62,63]
FDCT = MPT (n = 1) [58]
Inconclusive * (n = 1) [61]
HT
(n = 31)
FDCT > MPT (n = 28) [5,33,38–42,46,53,55,56,64–74,77–79,81–83]
FDCT = MPT (n = 2) [75,76]
Inconclusive * (n = 1) [80]
DMII
(n = 10)
FDCT > MPT (n = 9) [31,32,36,44,51,54,84–86]
Inconclusive * (n = 1) [43]
HIV (n = 14)
FDCT > MPT (n = 10) [30,37,57,87–89,91–94]
FDCT = MPT (n = 3) [34,50,90]
Inconclusive * (n = 1) [47]
Other (n = 1) FDCT = MPT (n = 1) [95]
* Several outcomes were observed (FDCT < MPT or FDCT > MPT or FDCT = MPT). See Table A2 (Appendix B) and
Table A3 (Appendix C) for additional information. FDCT, fixed-dose combination therapy; MPT, multipill therapy;
CVD, cardiovascular disease; DMII, diabetes mellitus type 2; LUTS/BHP, Lower urinary tract symptoms associated
with benign prostatic hyperplasia; HIV, human immunodeficiency virus.
3.5. Quality Assessment of the Included Studies
Figure 3 shows the risk of bias summary for all seven randomized controlled trials [35,45,48,
52,59,75,88]. As previously noted, blinding of participants was impossible due to the nature of the
intervention, that is, different pill burden, resulting in high risk of performance bias in all studies.
Thus, it was decided to be omitted from the overall risk of bias assessment. Based on the previously
determined criteria, two RCTs reached standards for having an overall low risk of bias [48,52], two
studies reached standards for having a medium risk of bias [35,59], and three studies were considered
as having a high overall risk of bias [45,75,88].
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Except for Matsumura et al. [75], which reported on the insignificant difference in adherence
between polypills and multipill therapy and which was assessed as having a high risk of bias,
all the other RCTs (n = 6, 86%) showed improved adherence when using polypills compared to
multipill therapy.
From 60 of the included observational studies, 39 (65%) were assigned eight or nine stars
according to the Newcastle–Ottawa rating and were, thus, considered as high-quality studies [5,33,36,
37,41–44,46,47,50,51,53–56,58,61–65,67,71,72,74,76,78–84,86,89–91,94]. There were 19 studies (32%) that
reached criteria for medium quality (six or seven stars) [30–32,34,38–40,49,57,60,68–70,77,85,87,92,93,95],
and only two studies (3%) were considered poor quality, with both having five stars assigned [66,73].
In 50 out of a total of 60 observational studies (83%), adherence to the polypill was shown to
be increased compared to multipill therapy. Of the high-quality studies, 31 out of 39 studies (79%)
also showed this outcome, which does not differ importantly from findings from the total number of
observational studies. Moreover, the ratio of studies with an insignificant difference in adherence to
polypill and multipill therapy is very similar for high- and medium-quality studies (4/39 or 10% vs.
2/19 or 11%, respectively). For a visual representation showing the number of studies with a certain
outcome concerning adherence per quality of cohort study, see Figure 4.
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4. Discussion
The main strength of our study is the broad range of included original peer-reviewed studies
and that no restrictions concerning the medical condition, type of patients, or adherence measures
were used in the research. Based on this systematic review, there is a connection between pill
burden and medication adherence in medical conditions such as hypertension, diabetes mellitus
type 2, cardiovascular diseases, and HIV. This is reflected by the fact that, in 56 out of 67 examined
studies (84%), patient adherence to single-pill fixed-dose combination therapy was significantly higher
compared to free-dose combination therapy with multiple pills. Most of the 17 previously conducted
meta-analyses and systematic reviews included in our research also suggested a positive effect of
polypills on patient adherence. However, four out of 17 studies (24%) did not reach the same conclusion;
either the findings were inconclusive [26,29] or FDCT was simply not shown to be superior to multipill
therapy [17,23]. It has to be acknowledged, however, that the number of analyzed articles in these
studies was either three [17,26], five [23], or six [29]; thus, they might not be highly representative.
Ten percent (n = 7) of the individual studies did not observe improved adherence in patients
receiving polypill therapy [34,50,58,75,76,90,95]. The authors of these articles suggested the following
methodological reasons for their results: (1) the number of participants was too small to obtain
significant results [34]; (2) calculation of MPR was made alternatively and therapeutic or in-class
switches were allowed for [58]; (3) the pill burden for some multipill therapy regimens was not high
enough to have a significant influence on adherence [34]; (4) the study period was not long enough to
detect differences between the polypill and multipill groups [75].
Interestingly, two out of 67 studies [61,80], dealing with CVD and HT, respectively, observed
both positive and negative outcomes regarding the influence of FDCT on adherence. For the study,
dealing with CVD [61], the article’s authors suggested that the reasons for decreased adherence in
patients taking polypills were adverse events. These were supposed to be falsely attributed to an active
ingredient, which the patients in question were not receiving before the start of the study [61]. Authors
of the other study dealing with HT, however, suggested a different reason for decreased adherence [80].
According to them, patients who were highly adherent to their previous treatment with free-combined
antihypertensive drugs may not have been taking both of their antihypertensive medications at the
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same time and as prescribed. Hence, although they were switched to the equivalent FDC, their blood
pressure lowered too much; therefore, they reduced the dose of FDCs on their own [80].
To our knowledge, no other previous systematic review in polypills and adherence covered as
many original peer-reviewed studies and such a broad range of medical conditions as this. Our findings
indicate that the rate at which polypill therapy is associated with higher adherence varies among
medical conditions. In most of the studies on CVD, HT, and DMII therapies, adherence increased
in patients with polypill therapy; however, in studies on HIV or LUTS therapies, no difference was
observed in four out of 15, that is, 27% of the studies. These differences in results can be partly
explained by the methodological issues already discussed above. Further research on diseases other
than CVD, HT, DMII, and HIV is needed to get a better understanding of whether and how the medical
condition influences the impact of reduced pill burden on adherence.
The research mainly revolves around cardiovascular polypills; the reason for this is probably the
abundance of patients suffering from CVD and HT [96]. Despite fewer studies on polypills for diabetes
and HIV and one for lower urinary tract symptoms associated with benign prostatic hyperplasia,
fixed-dose combination therapy was not introduced to other diseases in terms of its potential to
influence adherence. As this literature review shows promising results for polypills with 56 out of 67
included studies improving adherence, the research could be extended to a wider range of medical
conditions and a wider range of populations and health systems, as well as beyond high-income
countries. The current research on polypills is dominated by the research conducted in the USA,
reflecting their situation.
There are also some limitations concerning this systematic review. The first one is related to the
methodological quality of the selected studies. The results would be more valid if more of the study
designs were randomized controlled trials instead of retrospective and prospective cohort studies.
Since the study design differed between articles, it was also not possible to assess study quality using
only one universal method. Thus, two separate methods were used, one for randomized controlled
trials [11] and the other for observational studies [12]. Consequently, it was not possible to make
a joint summary of study quality assessment including all articles. Another limitation is related to
the countries and the medications included in the studies. Specifically, every country has different
public health concerns, as well as health systems, services, and finances, which influence medication
practices. Since most of the reviewed studies were from high-income countries, particularly from
the USA, a distorted image of the use of polypills in the rest of the world is possible. It must also
be acknowledged that patient adherence is affected by many variables, such as patient age, medical
condition, and clinical outcomes, which varied significantly in our selected articles. The assessment of
these factors was not the aim of this review, but they could have significantly influenced our findings.
Furthermore, due to the lack of articles regarding other diseases, it is not possible to conclude whether
polypills are associated with an increase in medication adherence on a general level. This can become
clear only when more studies regarding the effect of polypills on adherence in other diseases are
conducted. Moreover, there is some overlapping among previously published systematic reviews and
meta-analyses, as some articles were included in more than one of them, thereby giving those studies
more emphasis.
Another issue that must be acknowledged as a possible limitation to our study is the diversity of
methods for measuring adherence that were applied in the included studies. In 67 articles, 11 different
adherence measures were used, which makes the results of the studies more difficult to compare,
thereby adding a possible source of bias. The methods range, on the one hand, from assessing
prescription claims and the number of the pills taken (indirect methods) to analyzing questionnaires
and patient self-assessment, on the other hand (subjective methods) [75], all having specific advantages
and limitations. For example, indirect methods are a very technical way of measuring adherence,
but easy to apply to bigger datasets, which may explain their use in these studies. However, unlike
self-assessment-based methods, they do not cover other aspects of a patient´s life that also influence
adherence. Additionally, pill-count and prescription claim analyses do not guarantee that the patients
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were taking the prescribed medicines [40,49]. On the other hand, self-assessment is a very subjective
way of measuring adherence and is often prone to over-reporting the actual state [45,87]. In none of the
studies were direct methods of measuring adherence used (i.e., measuring blood concentration of the
active ingredients), which are the most objective methods, but also the most difficult, time-consuming,
and expensive, as well as being inconvenient for patients [48]. In the future, it might be useful to
consider the aspect of how patients perceive taking one instead of multiple pills in the methods for
assessing adherence. Finally, due to such substantial heterogeneity between studies in terms of study
design and reporting on the outcome, a pooled estimate of the effect of the pill burden on adherence
was not analyzed, which can be considered as one of the limitations as well.
Another issue that emerged while carrying out this systematic review relates to the vague use of
the terms “adherence” and “persistence.” Certain methods (e.g., duration to treatment discontinuation)
were defined as a measure of adherence in some of the studies, whereas the other studies stated
it as a method of assessing therapy persistence. In the future, clearer definitions and distinction
between these two terms and the methods used for measuring them should be made available to avoid
misconceptions about the aims of the studies.
The years of publication of selected articles indicate that there was increased interest in polypills
in the last years. Only seven of the selected articles (10%) were published before 2008, and 35 out
of a total of 67 studies (52%) were published in the last six years. One of the reasons for this rising
trend might be the fact that fixed-dose combination therapy shows promising results for improving
patient adherence.
Most of today’s commercially available polypills are intended for the treatment of only one
indication. However, since it was already established how beneficial FDCT can be for patients, another
interesting concept that is not yet applied very often, but is worth considering, is combining drugs
for different indications into one formulation. Between 2010 and 2015, two FDCs composed of active
pharmaceutical ingredients (APIs) for different comorbid diseases were already approved, both without
full clinical study data [97]. In the future, more emphasis could be given to such FDCs, since that
would reduce pill burden even more and, hopefully, have an even greater effect on patient adherence.
Even though this systematic review shows one of the potential benefits of polypill therapy,
some of its disadvantages should also be acknowledged. For example, if dosing titration is needed,
fixed-dose combination therapy can be inflexible if the appropriate dosage is not available in the form
of a polypill [98–101]. That could lead to exposure of patients to unnecessary therapy and even adverse
effects without added benefits [100]. Furthermore, if adverse effects occur, it cannot be possible for the
patient to determine which of the components is causing them [101]. Another possible issue is that
polypill therapy may be more expensive than multipill therapy [66,67,98].
All in all, the evidence shown in this systematic review constitutes a base for possible advantages
of polypill therapy over multipill therapy, at least in the investigated medical conditions, when tackling
the widespread and alarming problem of patient adherence to medication. Thus, the role of polypills
in clinical practice should not be neglected, even though their contribution to increasing adherence
is only partial. There are many other patient- and system-related factors, such as patient age and
socioeconomic status, health literacy, disease and medication beliefs, adverse effects, medical condition
and its seriousness, treatment costs, and clinical outcomes, which also play a major role in achieving
positive outcomes [48,52,61,80,84]. However, reducing the complexity of pill regimens, especially in
diseases where the number of pills can seem overwhelming for patients, could at least partly lead
to increased medication adherence and, therefore, also improved clinical outcomes. Nonetheless, to
better understand the role of polypills in clinical practice, a higher number of long-term randomized
controlled trials dealing with different medical conditions will be needed.
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5. Conclusions
This systematic review shows a connection between pill burden and medication adherence.
In most of the included studies, adherence to polypill therapy was significantly higher compared
to multipill therapy. Our findings indicate that the rate at which fixed-dose combination therapy is
associated with higher adherence varies between medical conditions. As this systematic review shows
promising results for polypills, research could be extended to a wider range of medical conditions,
populations, and health systems, as well as beyond high-income countries.
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Appendix A
Table A1. Summary of the systematic reviews and meta-analyses (n = 17) regarding the medical condition in focus, study aim, number and design of included studies,
and main results.
Author, Reference, Year of
Publication, Study Design
Medical Condition or
Disease in Focus Study Aim
Number and Design of
Studies Included Main Results
Various diseases (n = 1)
Van Galen et al. [29], 2014
Systematic review and
meta-analysis
HIV (n = 2),
tuberculosis (n = 3),
hypertension (n = 1)
To summarize and synthesize existing
evidence from RCTs about the effect on
adherence to FDCT versus the same
drugs administered as separate pills
6 RCTs
Administering drugs as FDC increased the
likelihood of optimal adherence (OR 1.33
(95% CI, 1.03–1.71)); however, the difference
was statistically significant only for HIV.
Other diseases only showed the same trend.
Bangalore et al. [13], 2007
Meta-analysis
Tuberculosis (n = 2),
hypertension (n = 4),
DMII (n = 2),
HIV (n = 1)
To evaluate the effect of FDCT on
patient adherence to medication
9: 3 RCTs, 6 retrospective
database analyses
Utilizing FDC resulted in 26% decrease in the
risk of non-compliance compared to the
free-drug therapy (RR: 0.74; 95% CI:
0.69–0.80; p < 0.0001).
Hypertension (n = 5)
Kawalec et al. [25], 2018
Systematic review with
meta-analysis and narrative
synthesis
Hypertension
To present an up-to-date evaluation of
the effectiveness of FDCs and free
equivalent combinations in
management of hypertension and to
get more accurate results by using
a stratified meta-analysis
Whole systematic review:
26 clinical studies,
2 systematic reviews
Meta-analysis: 12;
11 retrospective cohort studies,
1 nonrandomized trial
(assessing adherence)
FDC were shown to be associated with
an improvement in adherence in comparison
to free equivalent combination therapy; e.g.,
meta-analysis of 4 cohort studies showed
an increased adherence with FDCT in the
average MPR by 13.1% (95% CIs:
8.9%–17.2%, p < 0.001).
Du et al. [14], 2018
Meta-analysis
Hypertension
To assess the effect of FDCT on
medication adherence in comparison to
free-equivalent combination therapies
in management of hypertension
7 (assessing adherence):
6 retrospective studies,
1 prospective study
FDCT was associated with higher medication
adherence than free equivalent combination
therapies; mean difference was 14.92% (95%
CIs: 7.38%–22.46%).
Sherrill et al. [15], 2011
Meta-analysis
Hypertension
To compare healthcare resource use
costs, adherence, and persistence
between groups of patients on
single-pill and free-equivalent
combination therapies
7 retrospective studies
(assessing adherence)
The average MPR was 8% higher in the
patient group to prior antihypertensives and
14% higher in experienced FDCT patient
group, compared with corresponding
free-equivalent combination group.
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Author, Reference, Year of
Publication, Study Design
Medical Condition or
Disease in Focus Study Aim
Number and Design of
Studies Included Main Results
Gupta et al. [16], 2009
Meta-analysis
Hypertension
To compare compliance, persistence,
blood pressure control, and safety
between FDCTs and free-drug
combinations
5 (assessing adherence): 2 RCTs,
3 retrospective cohort studies
The use of FDCT was associated with
significantly better compliance (OR: 1.21, 95%
CIs: 1.03–1.43; p = 0.02).
Mallat et al. [26], 2016
Systematic review and
meta-analysis
Essential arterial
hypertension
To compare the effects of FDCT and
free combination therapy with blood
pressure lowering agents in the
management of essential hypertension
3 RCTs (assessing adherence)
Two articles reported no difference in
adherence between groups, one article
showed increased adherence in FDCT group.
CVD (n = 2)
Selak et al. [17], 2018
Meta-analysis
CVD
To assess the impact of FDCT on
achieving the 2016 European Society of
Cardiology guideline targets for blood
pressure, low-density lipoprotein,
cholesterol, and antiplatelet therapy
3 RCTs
No difference was observed between groups
in antiplatelet adherence (96% vs. 96%,
RR: 1.00, 95% CIs: 0.98–1.01).
Bahiru et al. [21], 2017
Systematic review
Atherosclerotic CVD
To study the effect of FDC therapy on
all-cause mortality, fatal and non-fatal
ASCVD events, adverse events, blood
pressure, lipids, adherence,
discontinuation rates, health-related
quality of life and costs
4 RCTs (assessing adherence) FDC therapy improved adherence by 44%(26% to 65%) compared with usual care.
Webster et al. [18], 2016
Meta-analysis
CVD To compare FDCT with usual care inpatients with CVD or at high risk 3 RCTs
Participants in the FDC group had higher
adherence than patients with usual care
(80% vs. 50%, RR: 1.58; 95% CIs: 1.32–1.90;
p < 0.001).
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Author, Reference, Year of
Publication, Study Design
Medical Condition or
Disease in Focus Study Aim
Number and Design of
Studies Included Main Results
Diabetes (n = 2)
Han et al. [28], 2012
Systematic review and
meta-analysis
DMII
To compare effects of FDCs and dual
therapy of
antihyperglycemic agents on glycemic
control and adherence
8 cohort studies
(assessing adherence)
Five comparisons FDC versus dual therapy
cohorts showed significantly higher MPR
with FDC (MD = 8.6% (95% CIs: 1.6–15.6);
p = 0.0162). Three comparisons showed
results for patients who switched from dual
therapy to FDC or stayed on dual therapy,
with higher MPR for patients who switched
to FDC (MD = 5.0% (95% CIs: 3.1–6.8);
p < 0.0001).
Hutchins et al. [22], 2011
Systematic review
DMII
To evaluate adherence, patient-reported
outcomes, costs, resource use and cost
effectiveness between FDCT and LDCT
8 cohort studies
(assessing adherence)
Adherence was improved with using FDCT
instead of LDCT.
HIV (n = 4)
Altice et al. [27], 2019
Systematic review and
meta-analysis
HIV
To study the relationship between
single or multiple tablet regimens and
treatment adherence and viral
suppression
Whole systematic review:
11 prospective or retrospective
non-randomized studies
(assessing adherence);
10 full texts and one
conference abstract
Meta-analysis: 8; 7 full texts and
one conference abstract
Polypills were associated with higher
treatment adherence than multipill therapy
in 10 studies: a 63% greater likelihood of
achieving ≥95% adherence (95% CIs:
1.52–1.74; p < 0.001) and a 43% increase in the
likelihood of achieving ≥90% adherence (95%
CIs: 1.21–1.69; p < 0.001).
Clay et al. [24], 2018
Systematic review,
meta-analysis
HIV
To compare single-pill to multi-tablet
regimens in HIV treatment by using
published data
Reporting on adherence: 30,
but only 8 observational studies
reported quantifiable data and
were included in the
meta-analysis.
Patients utilizing single-pill regimens were
significantly more adherent (OR: 1.96,
p < 0.001).
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Author, Reference, Year of
Publication, Study Design
Medical Condition or
Disease in Focus Study Aim
Number and Design of
Studies Included Main Results
Clay et al. [20], 2015
Meta-analysis
HIV
To compare patient adherence and
clinical and economic outcomes of
FDCT and multipill therapy regimens
Reporting on adherence: 20;
but only 5 having quantifiable
or analyzable data for
meta-analysis: 4 observational
studies, 1 economic
models-based study.
Patients on FDCT were more adherent than
patients on multipill therapy regimen of any
frequency (OR: 2.37, 95% CIs: 1.68–3.35;
p < 0.001; 4 studies).
Ramjan et al. [19], 2014
Meta-analysis
HIV
To compare the advantages of FDC
antiretroviral therapy to separate pill
therapy regimens for patients
and programs
Reporting on adherence: 10, but
only 7 included in the
quantitative analysis: 5 RCTs
and 2 retrospective cohort
studies.
RCTs showed better adherence in FDCT
group than in separate pill regimens
(RR: 1.10, 95% CIs: 0.98–1.22); observational
studies showed the same trend (RR: 1.17,
95% CIs: 1.07–1.28).
Tuberculosis (n = 1)
Albanna et al. [23], 2013
Systematic review and
meta-analysis
Tuberculosis
To assess different aspects of
management of tuberculosis using FDC
or free combination treatment
5 RCTs (assessing adherence) None of the studies favored FDCT.
FDCT, fixed-dose combination therapy; FDC, fixed-dose combination; RCT, randomized controlled trial; MPR, medication possession ratio; MD, mean difference; CVD, cardiovascular
disease; ASCVD, atherosclerotic CVD; HIV, human immunodeficiency virus; DMII, diabetes mellitus type II; CI, confidence interval; OR, odds ratio; RR, relative risk.
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Appendix B
Table A2. Summary of the original articles (n = 67) regarding aim, study setting, follow-up period, population, type of adherence outcome measures, and results.
Author, Reference, Year of
Publication, Study Country,
Study Design
Study Aim, Study Setting and
Follow-Up Period Study Population Outcome Measures Main Results (Concerning Adherence)
CVD (n = 11)
Castellano et al. [35], 2014,
Argentina, Paraguay, Italy
and Spain
Phase 1: observational,
prospective, cross-sectional study
Phase 2: randomized, controlled
clinical trial
Phase 1: to identify factors interfering
with adherence to CV medications for
secondary prevention after an acute
myocardial infarction.
Phase 2: to test the impact of
a polypill on adherence, blood
pressure, low-density lipoprotein
cholesterol, safety and tolerability.
Phase 1: 64 outpatient clinics in
Argentina, Brazil, Paraguay, Italy
and Spain
Phase 2: 63 clinics in Argentina,
Paraguay, Italy and Spain
Follow-up period: 9 months
Phase 2: 695 infarct patients
≥40 years of age with a history
of acute myocardial infarction
within the last 2 years (350 on
FDC therapy and 345 on
conventional
multipill treatment).
Adherence was
measured via Morisky
Medication Adherence
Scale and pill count.
Polypills showed a significantly higher
adherence in comparison with multiple
pills (50.8% vs. 41%, p = 0.019).
Lafeber et al. [59], 2014,
the Netherlands
Randomized controlled trial
To compare the morning and
evening administration of
a cardiovascular polypill and to
assess the effect of the polypill on
patients’ clinical outcomes,
adherence, and preference compared
to the separately administered
identically dosed drugs
University Medical Center Utrecht
Follow-up period: 18 weeks
78 patients with established
atherosclerotic CVD and
an indication for the use of
cardiovascular medication
(during the three treatment
periods of 6 weeks, each was
receiving every type of therapy
regimen (polypill in the
morning, polypill in the
evening, and mutlipill therapy
with individual drugs), but in
different sequences).
Adherence was
measured via
microelectronic
monitoring device and
Morisky Medication
Adherence Scale.
According to digital adherence
monitoring, adherence was 5.2% (95%
CIs: 1.4%–9.1%) higher when using the
polypill in the morning and 5.3% (95%
CIs: 1.4%–9.1%) higher when using the
polypill in the evening compared to
multipill therapy. Morisky scale
recognized non-adherence in 4 (5%)
participants when using the polypill in
the morning, in 6 (8%) participants when
using the polypill in the evening, and in
10 (13%) participants when using the
individual agents (p = 0.22).
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Patel et al. [45], 2014, Australia
Randomized controlled trial
To determine if polypills improve
adherence in high risk CVD patients
33 Australian health centers
Follow-up period: 18 months
623 patients ≥18 years of age
with high CVD risk (311
allocated to polypill treatment
and 312 to
conventional treatment).
Adherence was
measured via
self-reporting.
Patients on the polypill therapy reported
an adherence rate of 70.1% at study end,
while people on usual care reported
a 46.9% adherence (p < 0.001).
Selak et al. [48], 2014,
New Zealand
Randomized controlled trial
To investigate the impact of FDCT on
the adherence rate and risk factor
control in patients with high
cardiovascular risk
54 general practices all over
New Zealand
Follow-up period: 12 months
513 patients aged 18–79 years at
high risk of CVD (256 allocated
to FDC and 257 to usual care).
Adherence was
measured via
self-reporting.
Adherence in patients receiving FDCT
was higher compared to the two-pill
treatment (81% vs. 46%, p < 0.001).
Thom et al. [52], 2013, UK, India,
Ireland, the Netherlands
Randomized, open-label,
blinded-end-point clinical trial
To assess the impact of a polypill in
comparison to usual care on
adherence patterns, systolic blood
pressure and low-density
lipoprotein cholesterol
Patient data obtained via databases,
hospitals and general practices in
India, England, Ireland,
and the Netherlands
Follow-up period: 12 months
2004 patients ≥18 years of age
with high cardiovascular risk,
defined as either established
CVD, or an estimated 5-year
CVD risk of 15% or greater
(1002 allocated to FDC group
and 1002 to usual care)
Adherence was
measured via
self-reporting.
The FDCT group had significantly
improved adherence compared to the
usual care group (88% vs. 65%, p < 0.001).
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Schaffer et al. [61], 2017, Australia
Retrospective cohort study
To compare adherence in patients
initiating amlodipine/atorvastatin
therapy as an FDC or free
combination and to identify
subgroups benefiting most
from FDCs
Data retrieved via Australian
Pharmaceutical Benefits Scheme
Follow-up period: 24 months
9430 patients, who started their
therapy with study drugs either
as an FDC or in free
combination (3996 on FDC and
5434 on free
combination therapy).
Adherence was
measured via PDC.
Patients initiating on an FDC were more
likely to have near-perfect adherence
compared to those with the free
combination, if they were previously
statin adherent irrespective of amlodipine
dose (amlodipine 5 mg: OR = 1.61,
95% CIs: 1.38–1.87; amlodipine 10 mg:
OR = 2.39, 95% CIs: 1.63–3.51), or if they
were previously statin nonadherent and
initiated on the FDC with 5-mg
amlodipine (OR = 1.87, 95% CIs:
1.50–2.32). However, statin-naïve
initiating on FDCT with 10-mg
amlodipine were less likely to have
near-perfect adherence (OR = 0.60, 95%
CIs: 0.41–0.88) and more likely to have
early nonadherence (OR = 1.73,
95% CIs: 1.17–2.55) compared with the
free combination.
Bartlett et al. [58], 2016, Australia
Retrospective cohort study
To compare adherence and
persistence in patients who add
ezetimibe to statin therapy as
a separate pill combination or FDC
Data retrieved via Australian
Pharmaceutical Benefits Scheme
Follow-up period: 6 months
9391 patients, who initiated
ezetimibe as separate pill or
ezetimibe in FDC (3651 on
multipill therapy and 5740 on
FDC therapy).
Adherence was
measured via MPR.
Adherence was similar in both groups;
mean MPRs: multipill therapy = 0.99
(95% CIs: 0.98–1.01) and FDC = 0.97
(95% CIs: 0.95–0.99).
Pharmaceutics 2020, 12, 190 23 of 55
Table A2. Cont.
Author, Reference, Year of
Publication, Study Country,
Study Design
Study Aim, Study Setting and
Follow-Up Period Study Population Outcome Measures Main Results (Concerning Adherence)
Kamat et al. [63], 2011, USA
Retrospective cohort study
To compare adherence between
single- and multipill therapies with
lipid-modifying drugs
Data retrieved via HealthCore
Integrated Research Database
Follow-up period: 36 months
42,460 patients ≥18 years of age
newly initiating FDC
dyslipidemia therapy
(38,847 patients) or equivalent
multipill therapy
(3613 patients).
Adherence was
measured via MPR.
The mean PDC was 0.76 (±0.26) and 0.70
(±0.27) in the first 3 months of treatment,
0.54 (±0.40) and 0.45 (±0.40) in the second
3 months of treatment, and 0.50 (±0.41)
and 0.41 (±0.43) for the remaining 30
months for FDC and multipill groups,
respectively. Average PDC was
significantly higher in the SPC group
(0.56 ± 0.34) than in the LDC group
(0.47 ± 0.33), p < 0.0001.
Balu et al. [62], 2009, USA
Retrospective cohort study
To compare adherence between
patients treated with the FDC
multipill combination therapy, to
assess the relationship between
optimal adherence and
CVD-associated total healthcare
resource utilization and
healthcare cost
Data retrieved via HealthCore
Integrated Research Database
Follow-up period: 12 months
8988 patients ≥18 years of age
newly initiating FDC (niacin
extended-release (NER) and
lovastatin (NERL); 6638
patients) or multipill
combination therapies (NER
and simvastatin (NER/S); 1687
patients, or lovastatin (NER/L);
663 patients) between
index dates.
Adherence was
assessed via MPR.
NER/S and NER/L patients were 31.3%
(95% CIs: 22.9%–39.5%) and 39.1%
(95% CIs: 26.7%–49.4%) less likely to be
adherent than NERL patients (p < 0.01).
LaFleur et al. [60], 2006, USA
Retrospective cohort study
To compare patient adherence
between different pill regimen of
lipid-lowering drugs
Patient data retrieved from
RxAmerica database
Follow-up period: mean ca.
12 months
1672 patients who started the
therapy with any of the study
drugs in the selection years
(among them, 224 in the ERNL
(= polypill) group and 347 in
the ERN-S (= combination
therapy) group.
Adherence was
measured via MPR.
Adherence rates for ERNL (= polypill)
and ERN-S (two pills) groups were
significantly different: 72.5% vs. 75.8%
(p = 0.033).
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Taylor and Shoheiber [49],
2003, USA
Retrospective cohort study
To check if adherence is better for
a single-pill regimen vs.
a multiple-pill regimen.
Patient data retrieved from
a managed care organization that
provides benefits for members
enrolled in various health plans
Follow-up period: 12 months
5732 patients aged 18–64 years
with a diagnosis code for HT
and who were treated with one
of the two study regimens and
filled at least two prescriptions
for their regimen on two
different dates during the study
period (2754 receiving FDC and
2978 receiving
multipill therapy).
Adherence was
measured via MPR.
The overall adherence rate in the polypill
group (80.8%) was significantly higher
than in the multipill group (73.8%),
p < 0.001.
Hypertension (n = 31)
Matsumara et al. [75], 2012, Japan
Randomized controlled trial
To investigate if medication
adherence in hypertensive patients
would improve with SPC
29 hospitals or clinics in Japan
Follow-up period: 6 months
207 hypertensive patients
≥20 years of age (103 allocated
to FDC therapy and 104 to
multipill therapy).
Adherence was
measured via residual
pill count.
No significant differences were found in
adherence rate between SPC and
multiple-pill groups (p = 0.89).
Bramlage et al. [66], 2014, Austria,
Belgium, Germany,
the Netherlands, and Switzerland
Prospective, non-interventional
multicenter study
To get information on safety,
tolerability and efficacy of the FDC of
olmesartan/amlodipine/hydrochlorothiazide
in daily practice and to check the
impact of polypills on adherence in
patients with HT
Primary care practice in five
European countries (Austria,
Belgium, Germany, the Netherlands,
and Switzerland)
Follow-up period: 6 months
14,979 patients ≥18 years of age
with essential HT and new
treatment with an FDC.
Adherence was
measured via
a Morisky Medication
Adherence Scale.
Mean adherence raised from 6.0% to 6.9%
when switching from multipill to FDCT
(p < 0.001).
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Kumagai et al. [73], 2012, Japan
Prospective, multicenter,
observational study
To investigate the impact of FDC
treatment on adherence, blood
pressure and healthcare costs
Several clinics and hospitals in Japan
Follow-up period: 3 months
196 patients with hypertension
treated with free-drug
combinations of ARB and
amlodipine; free-drug
combinations were replaced
with the same dose of the FDC.
Adherence was
measured via
self-reported
pill-count.
Adherence was significantly improved
after switching from free combination to
FDC therapy (p < 0.01).
Ah et al. [64], 2019, Korea
Retrospective cohort study
To compare adherence and
persistence between single-pill and
free equivalent combination and
between two single-pill combinations
as initial treatment hypertensive
patients who also received
prepackaged medications
from the pharmacy
Data retrieved via Korean national
claims database
Follow-up period: 12 months
40,350 patients ≥18 years of age
with ICD-10 code of
hypertension and started on
combination regimen consisting
of an ARB and either a thiazide
diuretic or CCB (20,175 on
multipill therapy and 20,175 on
single-pill therapy).
Adherence was
measured via MPR.
The single-pill cohort had 30% higher
medication adherence (OR 1.31, 95% CIs:
1.25–1.37) than the free pill cohort
(p < 0.05).
Pharmaceutics 2020, 12, 190 26 of 55
Table A2. Cont.
Author, Reference, Year of
Publication, Study Country,
Study Design
Study Aim, Study Setting and
Follow-Up Period Study Population Outcome Measures Main Results (Concerning Adherence)
Bramlage et al. [67],
2018, Germany
Retrospective cohort study
To assess the effect of FDCs on
persistence, adherence,
and medication costs, to acquire data
regarding the differences in patient
characteristics and comedications
between patients prescribed an FDC
and those prescribed a free-dose
combination, and to assess
motivations behind prescription of
one or another of the combination
therapy types
Data retrieved via IMS®Disease
Analyzer, which contains medical
records provided by 2500 physician
practices in Germany
Follow-up period: 12 months
81,958 hypertensive patients
who filled at least one
prescription for one of two
drugs combinations, either as
a single-pill FDC or as a two-pill
free-dose combination (10,938
on ramipril/amlodipine FDCT,
60,525 on ramipril/amlodipine
free dose therapy, 1413 on
candesartan/amlodipine FDCT,
9082 on candesartan/amlodipine
free dose therapy).
Adherence was
assessed via MPR.
The mean MPR was higher for patients
prescribed FDC compared to those taking
a free-dose combination
(ramipril/amlodipine: 0.72 vs. 0.58,
p < 0.001; candesartan/amlodipine:
0.92 vs. 0.79, p < 0.001).
Degli Esposti et al. [69], 2018, Italy
Retrospective cohort study
To assess the changes in treatment
adherence in patients who switched
from single-pill or two-pill therapy
to FDCT
Data retrieved via administrative
databases involving three local health
units in three Italian regions
Follow-up period: 24 months
24,020 patients ≥18 years of age
receiving at least one
prescription of selected
antihypertensive drugs in
selection period (1093 with
two-pill treatment, 302 switched
to FDCT, 791 did not; 22,927
with MT, 3295 switched to
FDCT, 19,632 did not).
Adherence was
measured via PDC.
Adherence rose significantly among the
subjects who switched to FDC from
two-pill therapy (+13%, p < 0.001), while
it was almost unchanged or slightly
decreased among the subjects who did
not (−4%, p < 0.001).
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Ho et al. [71], 2018, Taiwan
Retrospective cohort study
To compare the clinical outcomes of
FDC vs. free combinations of
renin–angiotensin system inhibitor
and thiazide diuretic in
hypertension management
Data retrieved via National Health
Insurance Research Database
of Taiwan
Follow-up period: at least 12 months
17,568 patients newly diagnosed
with hypertension aged ≥18
years who were prescribed with
FDC (13,176 patients) or free
combination (4,392 patients) of
renin–angiotensin system
inhibitors and thiazide diuretic.
Adherence was
measured via PDC.
FDC was associated with better
adherence (PDC 58.01% vs. 46.96%;
p < 0.001) than free combination therapy.
Tilea et al. [77], 2018, Romania
Retrospective
cross-sectional study
To assess the level of adherence to
antihypertensive treatment and
analyze how FDCT affects it
Family medicine practice in Tirgu
Mures, Romania
Follow-up period: 48 months
525 patients ≥18 years of age,
newly diagnosed with HT, who
started with therapy that
continued for at least
3 consecutive months (90 on
FDCT in the beginning,
173 in the end).
Adherence was
measured via
prescription
records review.
Interventions based on FDC during all 4
years of study showed significantly
higher adherence compared to
interventions with single active
ingredients (p = 0.001).
Verma et al. [79], 2018, Germany
Retrospective cohort study
To compare clinical outcomes and
patient adherence with FDC therapy
and multipill therapy
Data retrieved via Ontario Drug
Benefit database
Follow-up period: 5 years
13,350 patients ≥66 years of age
who were new users of
antihypertensive therapy (6675
on multipill therapy and 6675
on FDCT).
Adherence was
measured via the time
to the first instance of
discontinuation
and PDC.
The median time to the first
discontinuation of therapy as well as the
PDC was higher in FDC group (191 days,
70%) than in multipill group (150 days,
42%; p < 0.01).
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Lauffenburger et al. [74],
2017, USA
Retrospective cohort study
To investigate patterns of
antihypertensive therapy initiation
and compare adherence and
persistence between patients
initiating FDC and single-pill
therapies
Data retrieved via a large national
health insurer
Follow-up period: 12 months
484,493 patients ≥18 years of
age, who initiated an oral
antihypertensive medication
therapy (78,958 on FDC, 383,269
on single-pill therapy, 22,266 on
multipill therapy).
Adherence was
measured via PDC.
Patients with FDC therapy were 13%
more likely to be adherent than patients
on single-pill therapy (RR: 1.13; 95% CIs:
1.11–1.14; p < 0.05).
Tung et al. [53], 2017, Taiwan
Retrospective cohort study
To compare the clinical outcomes of
FDCs and free combinations of ARB
and CCB in management of HT
Data retrieved via National Health
Insurance Research Database
of Taiwan
Follow-up period: 2.1 years (mean)
5680 hypertensive patients ≥18
years of age, who were
prescribed an ARB and
a dihydropyridine CCB (1136
on FDC therapy and 4544 on
free combination therapy).
Adherence was
measured via PDC.
Adherence was higher among patients
receiving an FDC compared with the free
combination group (PDC ≥80%: 64.97%
vs. 56.88%; PDC from 50% to 80%:
22.55% vs. 24.16%; PDC <50%: 12.48% vs.
18.95% (p < 0.001)).
Levi et al. [42], 2016, Italy
Retrospective cohort study
To compare adherence to FDCT and
LDCT in primary care
Data retrieved via HS IMS Health
LPD, an Italian general
practice database
Follow-up period: 6 months
6612 hypertensive patients ≥18
years of age, who were treated
with olmesartan/amlodipine as
an extemporaneous
combination or FDC (2090 on
extemporaneous combination
and 4522 on FDCs).
Adherence was
measured via PDC.
55.1% of the patients treated with FDC
were found to be highly adherent (PDC
>80%), whereas, among patients treated
with the extemporaneous combination,
only 15.9% were highly adherent
(p < 0.001).
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Sonawane et al. [76], 2016, USA
Retrospective cohort study
To compare the adherence of
alternative treatment modification
strategies and characterize the factors
associated with adherence after
such modifications
Data retrieved via BlueCross
BlueShield of Texas commercial
claims data
Follow-up period: 12 months
5998 hypertensive patients aged
≥18 years who received
treatment modifications (1395
on free-pill strategies and 1207
on FDC therapy).
Adherence was
measured via PDC.
Adherence for FPC and FDC strategies
was 0.67 ± 0.25 and 0.69 ± 0.29,
respectively, which was not statistically
significant (p < 0.05).
Hsu et al. [5], 2015, Taiwan
Retrospective cohort study
To compare adherence and
persistence in hypertensive patients
on FDCT and LDCT among newly
diagnosed hypertensive patients
Patient data obtained from the
National Health Insurance Research
Database (NHIRD)
Follow-up period: 24 months
7348 newly diagnosed HT
patients ≥20 years of age (5725
on FDC therapy and 1623 on
free combination therapy).
Adherence was
measured via MPR.
Adherence was higher for patients on
FDCT than patients on free dosing: 66.6%
vs. 63.9% after six months; 52.6% vs.
46.7% after one year; 42.1% vs. 32.5%
after two years (all p < 0.001).
Machnicki et al. [82], 2015, USA
Retrospective cohort study
To assess whether
amlodipine/valsartan/hydrochlorothiazide
SPC is associated with improved
adherence, persistence, and reduced
healthcare utilization and costs
compared to the FCT
Data retrieved using the Truven
MarketScan Commercial and
Medicare Supplemental Database
Follow-up period: 12 months
14,594 hypertensive patients
≥18 years of age (10,800 in
single-pill group, 3794 in free
combination group).
Adherence was
measured via PDC
and MPR.
Patients on SPC exhibited higher
adherence according to MPR (85.7% vs.
77.0%) and mean PDC (73.8% vs. 60.6%),
all p < 0.0001.
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Degli Esposti et al. [70], 2014, Italy
Retrospective cohort study
To investigate the reasons for
prescribing polypills and the
influence of polypills on adherence in
hypertensive patients.
Three Italian local health units
(patient data retrieved via the
Medications Prescription Database)
Follow-up period: 6 months
21,008 hypertensive patients
≥18 years of age with a 6-month
history of receiving free
combination treatment (2395
patients) or polypill treatment
(18,613 patients).
Adherence was
measured via PDC.
An increased percentage of patients who
switched to FDCT were adherent: +24%
when coming from a two-pill regime and
+42% when coming from single-pill
regime (p < 0.001).
Tung et al. [78], 2014, Taiwan
Retrospective cohort study
To compare the clinical outcomes,
healthcare costs, persistence,
and adherence of HT treatment with
an FDC of amlodipine/valsartan and
free-drug combinations of ARB
and CCB
Data retrieved via the National
Health Insurance Research Database
(NHIRD) of Taiwan
Follow-up period: 15 months
16,505 patients ≥18 years of age
with the diagnosis of HT (13,204
in FDC group FDC, 3301 in
combination therapy group).
Adherence was
measured via PDC.
The FDC group had a significantly higher
PDC than the combination therapy group
(80.35% vs. 72.57%, p < 0.001).
Wang et al. [80], 2014, Taiwan
Retrospective cohort study
To assess the effect of single-pill
formulations on adherence in
hypertensive patients
Patient data retrieved from the
Taiwanese National Health
Insurance database
Follow-up period: 12 months
896 patients who switched from
free pill combination therapy to
FDC therapy of the
same compound.
Adherence was
measured via MPR.
In patients with low or intermediate
preindex adherence (n = 729), switching
to SPCs resulted in improved MPR (36%
difference; 95% CIs: 33%–39%; p < 0.001).
However, patients with high preindex
adherence (n = 167) switching to SPCs
resulted in a lower MPR (−13% difference;
95% CIs: −17% to −9%; p < 0.001).
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Xie et al. [81], 2014, USA
Retrospective cohort study
To assess what the impact of the pill
burden is on adherence in
hypertensive patients
Data retrieved via health care claims
from the MarketScan Commercial
and Medicare Supplemental database
Follow-up period: 12 months
17,465 hypertensive patients
≥18 years of age, who were
prescribed three
antihypertensive agents in the
form of single-, double- or
triple-pill regimens (8516 in
single-pill group, 7842 in
double-pill group, 1107 in
triple-pill group).
Adherence was
measured via PDC.
Patients in the double-pill cohort and
triple-pill cohort were 55% and 74%,
respectively, less likely to be adherent
than patients receiving only one pill
(p < 0.001).
Panjabi et al. [83], 2013, USA
Retrospective cohort study
To assess the impact of fixed- versus
loose-dose triple-combination
therapy on adherence, clinical,
and economic outcomes in patients
with hypertension
Data retrieved from a large US health
plan associated with OptumInsight
Follow-up period: at least 12 months
16,290 patients initiating triple
therapy with an ARB, ACEi, or
BB plus amlodipine and
hydrochlorothiazide (10,696 on
two-pill therapy (FDC +
a second pill) and 5594 on
a three separate pills therapy).
Adherence was
assessed via PDC.
Mean PDC was greater in patients
receiving two-pill therapy (ARB cohort:
three-pill = 0.41, two-pill = 0.53; ACEi
cohort: three-pill = 0.43, two-pill = 0.50;
BB cohort: three-pill = 0.42,
two-pill = 0.55; p < 0.001).
Baser et al. [65], 2011, USA
Retrospective cohort study
To compare adherence of
valsartan/amlodipine SPC to
ARB/CCB multiple-pill
free combination
Data retrieved via US commercial
healthcare insurance claims
Follow-up period: 12 months
12,628 hypertensive patients
≥18 years of age (3259 in
single-pill group, 9369 in free
combination group).
Adherence was
measured via PDC.
Patients on SPC were 1.38 times more
adherent to their therapy than multiple
pill users (95% CIs: 1.24–1.53).
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Hussein et al. [72], 2010, USA
Retrospective cohort study
To compare the adherence between
polypill and two-pill regimen of the
same drugs (statin + CCB)
Patient data obtained from the Health
Plan Claims (US) database
Follow-up period: 6 months
35,430 patients ≥18 years of age
with a pharmacy claim for
single-pill
amlodipine/atorvastatin or
claims for both a CCB and
a statin within any 30-day
window in a selection year
(patients were categorized into 4
cohorts according to use of CCB
and/or statin therapies before
the index date and within each
cohort based on receiving FDC
or multipill therapy).
Adherence was
measured via PDC.
Adherence rates were overall higher for
polypill groups and varied depending on
patients’ previous treatment experiences.
The differences in adherence range from
no significant difference (OR = 1.00) in
naïve patients to significantly higher
adherence (OR = 2.81, p < 0.001) in the
experienced cohort.
Yang et al. [55], 2010, USA
Retrospective cohort study
To compare compliance, persistence,
health care resource utilization and
costs among hypertensive patients on
FDCT and LDCT
Data retrieved via Thomson Reuters
MarketScan Commercial and
Medicare Supplemental Databases
Follow-up period: 6 months
579,851 patients ≥18 years of
age initiating on either of the
selected FDC therapies (382,476
patients) or the equivalent
free-pill therapies
(197,375 patients).
Adherence was
measured via MPR.
Patients receiving FDCT showed
significantly higher MPR than patients on
free-pill therapies (72.8% vs. 61.3%; 95%
CI: 11.4%, 11.7%; p < 0.05).
Zeng et al. [56], 2010, USA
Retrospective cohort study
To assess adherence to ARB/CCB FDC
therapy compared with
free-pill combination
Data retrieved via MedImpact
Healthcare Systems database
Follow-up period: 12 months
4525 hypertensive patients
≥18 years of age initiating on
either of selected FDC (2213
patients) or free-pill therapies
(2312 patients).
Adherence was
measured via PDC.
Patients in the FDC group were
significantly more likely to adherent
(OR = 1.90, p < 0.001) compared to
patients on free combination therapy.
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Chapman et al. [68], 2009, USA
Retrospective cohort study
To compare the rate of adherence
between patients on one polypill and
patients with the same drugs in
separate pills
Data retrieved using PharMetrics
Patient-Centric Database
Follow-up period: 6 months
4556 hypertensive patients
≥18 years of age prescribed
amlodipine who switched to
amlodipine/atorvastatin FDC
(1139 patients) or added a statin
to their amlodipine regimen
(3417 patients).
Adherence was
measured via PDC.
After 180 days, the follow-up showed
that patients on the polypill had a greater
improvement in adherence in
comparison to multiple pill cohort: 50.8%
vs. 44.3% (p < 0.001).
Hess et al. [41], 2009, USA
Retrospective cohort study
To evaluate medication compliance,
persistence and hypertension-related
expenditures among patients that
switched from FDC to
free-combination therapy
Data obtained from the Thomson
Medstat MarketScan database
Follow-up period: 12 months
14,449 patients (7224 switching
to free combination therapy and
7225 controls continuing their
FDC therapy) were enrolled.
Adherence was
measured via MPR.
Adherence among the patients
continuing on FDC therapy was 22.1%
higher (p < 0.001) compared to the
patients who switched to free
combination therapy.
Brixner et al. [33], 2008, USA
Retrospective cohort study
To compare the adherence,
persistence and medication costs
between single- and multipill drugs
Data retrieved via IHCIS National
Managed Care Benchmark Database
Follow-up period: 12 months
8711 hypertensive patients ≥18
years of age, who were
prescribed study drugs in
combination and had at least
110 days of
recorded data during which no
other antihypertensive
medications were prescribed
before the start of therapy (8510
in FDC group, 561 in
multipill group).
Adherence was
measured via MPR.
Adherence in patients receiving FDCT
was higher compared to the multipill
treatment: adherence rates were 64.2%
for FDCT and 57.6% for LDCT (p < 0.001).
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Dickson and Plauschinat [39],
2008, USA
Retrospective cohort study
To investigate the difference between
FDCs and separate drugs in
adherence and total costs
Patient data retrieved from South
Carolina Medicaid database
Follow-up period: 12 months
5704 patients aged 65–100 years
who received at least two
prescriptions for study drugs in
one of the selection years (2336
in FDC group and 3368 in free
combination group).
Adherence was
measured via MPR.
Adherence was significantly higher in
patients receiving FDCT than patients
receiving free-dose therapy: 63.4% vs.
49.0% (p < 0.0001).
Dickson and Plauschinat [38],
2008, USA
Retrospective cohort study
To assess adherence with
antihypertensive therapy among
African American and White
Medicaid patients receiving FDC or
free combination therapy
Patient data retrieved from the South
Carolina Medicaid database
Follow-up period: 12 months
4076 patients aged 18–100 years
who received at least two
prescriptions for study drugs in
one of the selection years (3363
in the FDC group and 713 in the
free combination group).
Adherence was
measured via PDC.
Adherence was significantly higher in
patients on FDCT compared to LDCT:
58.6% vs. 48.1% (p < 0.05).
Patel et al. [46], 2008, USA
Retrospective cohort study
To investigate if the adherence in
hypertensive patients is better with
an FDC than with multiple pills
Patient data retrieved from
MedImpact Healthcare Systems
Follow-up period: 6 months
4703 patients ≥18 years of age
who started a CCB or statin
treatment simultaneously or
within 30 days (5 cohorts, only
one (n = 795) receiving
polypill therapy).
Adherence was
measured via PDC.
After 180 days, the adherence rates of the
polypill group were 9%–17% higher than
those of other groups (p < 0.001)
After one year, 63.9% of FDCT patients
were adherent, while only 33.1%–43.6%
were adherent in the group with the
separate pills (p < 0.001).
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Gerbino and Shoheiber [40],
2007, Italy
Retrospective cohort study
To check differences in adherence
patterns between an antihypertensive
polypill and the drugs
taken separately
Data retrieved via a pharmacy claims
database of a managed care
organization in the USA
Follow-up period: 12 months
6206 hypertensive patients, who
received at least two
prescriptions for FDC or
double-pill therapy (2839 in
FDC group, 3367 in
double-pill group).
Adherence was
measured via MPR.
Adherence rates were significantly higher
in the FDCT group in comparison to the
double-pill group: 87.9% vs. 69.2%
(p < 0.0001).
Diabetes (n = 10)
Rombopoulus et al. [85],
2015, Greece
Prospective cohort study
To evaluate the differences in the
adherence in DMII patients on FDC
and free-dose therapy of the
selected drugs
Multiple centers in Greece
Follow-up period: 24 weeks
659 diabetic patients aged >18
years with inadequate glycemic
control with metformin
monotherapy (366 on FDC and
293 on free-dose therapy).
Adherence was
measured via
a questionnaire.
In FDC group, 98.9% of patients were
compliant, compared to 84.6% in
free-dose group (p < 0.005). The odds
ratio for FDC vs. free-dose group was
18.9 (95% CIs: 6.2–57.7; p < 0.001).
Lokhandwala et al. [86],
2015, USA
Retrospective cohort study
To compare persistence, adherence
and economic outcomes between
diabetic patients using FDC and
LDC products
Data retrieved via MarketScan
Commercial and Medicare
Supplemental Databases
Follow-up period: 12 months
23,361 patients ≥18 years of age
with DMII and one additional
oral anti-diabetic prescription of
the same regimen (FDC/LDC) as
the index prescription; 12,590 on
FDCT and 10,771 on LDCT.
Adherence was
measured via MPR.
FDC patients had significantly higher
rate of adherence than patients on LDCT
(OR = 1.28; 95% CIs: 1.20–1.36; p < 0.001).
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Vittorino Gaddi et al. [84],
2013, Italy
Retrospective cohort study
To evaluate antidiabetic drug
adherence between MT, LDCT,
and FDCT
Patient data obtained via the
ARNO database
Follow-up period: 12 months
169,375 diabetes patients with at
least one oral antidiabetic
prescription claim (91,816 in MT
group, 31,674 in FDCT group
and 19,573 in LDCT group;
15.5% were excluded due to
therapy switch in the
follow-up period).
Adherence was
measured via MPR.
Adherence rates were higher in the FDCT
group (68.5%) than in LDCT group
(60.3%) (p < 0.05).
Barner [31], 2011, USA
Retrospective cohort study
To compare the adherence and costs
between MT, LDCT, and FDCT in the
treatment of DMII
Data retrieved via Texas Medicaid
prescription claims database
Follow-up period: at least 12 months
270 patients aged 18–65 years
prescribed FDCT with
pioglitazone and metformin in
post index period and the
analogous LDCT or MT in pre
index period.
Adherence was
measured via MPR.
There was a significant increase in
adherence of 8.9% (76.0% to 82.8%) when
switching from LDCT to FDCT
(p = 0.0081).
Thayer et al. [51], 2010, USA
Retrospective cohort study
To assess changes in adherence and
HbA1c in diabetes patients on
different drug regimes
Data obtained via two large databases
(not specified)
Follow-up period: at least 6 months
16,490 patients ≥18 years of age
with 1 or more prescription fills
for rosiglitazone, a sulfonylurea,
or rosiglitazone/glimepiride
FDCT during the identification
period (patients were grouped
according to baseline and
follow-up period treatment
plan; 2518 switched from mono
to dual therapy, 543 from MT to
FDCT, 13,145 remained on dual,
284 from dual to FDCT).
Adherence was
measured via MPR.
Switching from dual therapy to FDC
therapy showed a statistically significant
increase in adherence rate (p < 0.001).
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Cheong et al. [36], 2008, USA
Retrospective cohort study
To check the influence of multiple
drug regimens (FDCT/dual therapy)
on patient adherence
Patient data retrieved via the Texas
Medicaid prescription
claims database
Follow-up period: 12 months
22,512 patients aged 22–89
years, who were prescribed
an oral antidiabetic FDCT or the
analogous dual therapy during
the identification period (7750
FDCT users and 14,762 dual
therapy users).
Adherence was
measured via MPR.
Patients on FDCT had a higher MPR than
dual therapy users: 78.6% vs. 77.2%
(p < 0.001). Patients who switched from
dual therapy to FDCT saw an increase in
MPR of 12.4%, whereas people who
continued dual therapy only saw a rise of
5.1% (p < 0.001).
Pan et al. [44], 2008, USA
Retrospective cohort study
To compare the patient adherence
between single-pill (FDCT) and
two-pill regimen
Patient data retrieved via the Medstat
MarketScan database
Follow-up period: 6 months
9170 patients ≥18 years of age
prescribed metformin or
sulfonylurea or both before July
2000 and both metformin and
sulfonylurea concurrently
(either separately or FDC) after
August 2000 (2275 FDC users
and 6895 non-FDC users).
Adherence was
measured via MPR.
The adherence to the FDCT in
comparison to the two-pill regimen was
12.8% higher (p = NA).
Vanderpoel et al. [54], 2005, USA
Retrospective cohort study
To observe the changes in adherence
rates in patients switching from
mono- or dual therapy to a FDCT
Data retrieved via pharmacy
claims database
Follow-up period: 6 months
16,928 patients ≥18 years of age
with at least one pharmacy
claim for rosiglitazone or
metformin during the
identification period (patients
were grouped according to
treatment change from preindex
to postindex period; 14,291
remained on mono therapy,
1230 on dual therapy, 931
switched from mono to dual,
349 from mono to FDCT, 127
from dual to FDCT).
Adherence was
measured via MPR.
A significant improvement has been
observed for patients switching from
dual therapy to FDCT (3.5% vs. −1.3%,
p < 0.005).
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Blonde et al. [32], 2003, USA
Retrospective cohort study
To check the impact of single-pill
drugs on HbA1c values and
adherence rates in DMII patients
Patient data retrieved via Medco
Health Solutions and
Quest Diagnostics
Follow-up period: 6 months
1421 patients aged 18–80 years
who initiated single-pill or
multipill therapy and had A1C
measurements at baseline and
within 76–194 days of initiating
combination therapy (471 on
multipill therapy and 950 on
single-pill therapy).
Adherence was
measured via MPR.
Patients were more adherent to the
polypill in comparison to two-pill
regimen: 84% vs. 76% (p < 0.0001).
Melikian et al. [43], 2002, USA
Retrospective cohort study
To investigate if adherence is different
in diabetes patients with different
drug regimens (FDCT, MT,
combination therapy)
Patient data obtained via pharmacy
claims from a pharmacy benefit and
medical-management company
Follow-up period: 6 months
6502 patients ≥18 years of age
who had an index pharmacy
claim for an oral antidiabetic
and were continuously enrolled
in the health plan (4545
receiving metformin MT, 1651
glyburide MT, 219 combination
therapy (59 of those switched to
FDCT), 87 FDCT).
Adherence was
measured via MPR.
For newly diagnosed diabetics, there was
no significant difference in adherence
between the therapies.
Patients switching from combination
therapy to FDCT (pill burden reduction)
showed a better adherence with FDCT:
71% vs. 87% (p < 0.001).
HIV (n = 14)
Langebeek et al. [88], 2014,
the Netherlands, Belgium
Randomized controlled trial
To investigate the effect of simplified
regimens (1 pill/multiple pills) on
adherence, life quality and
treatment satisfaction
11 different sites in Belgium and
the Netherlands
Follow-up period: 24 months
120 HIV patients (59 on
multipill therapy and 61 on
single-pill therapy).
Adherence was
measured via
Simplified Medication
Adherence
Questionnaire.
Single pill therapy resulted in better
adherence than multipill therapy
(p = NA).
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Arrabal-Duran et al. [90],
2017, Spain
Observational prospective study
To data on the effectiveness of
switching to an FDC regimen in HIV
patients with sustained
virological suppression
Gregorio Marañon University
Hospital, Madrid, Spain
Follow-up period: 96 weeks
57 HIV patients whose previous
therapy was based on
twice-daily therapy regimen
and switched to the examined
FDC therapy.
Adherence was
measured via PDC.
The proportion of patients with
adherence <90% improved from 15.5% to
10.4% (p = 0.915), when they switched to
FDC therapy, but this difference is not
statistically significant.
Chen et al. [91], 2016, USA
Observational prospective study
To study adherence barriers
associated with medication regimen
complexity and simplification
Patients in Atlanta, Georgia
Follow-up period: 6 weeks
750 HIV patients aged ≥18 years
receiving antiretroviral therapy
(166 patients on FDC, 300 taking
single-dose multipill regimen,
284 taking multi-dose
multipill regimen).
Adherence was
measured via
pill count.
A higher number of patients in polypill
group (76%) achieved ≥85% adherence
compared to both the group taking
single-dose (68%) and the group taking
multi-dose multipill regimen (66%);
p < 0.043.
Buscher et al. [34], 2012, USA
Prospective cohort study
To study the impact of antiretroviral
therapy regimen on adherence in new
HIV patients (FDC vs. LDC and
once-daily vs. twice-daily dosing)
Houston, TX
Follow-up period: 18 months
99 newly diagnosed HIV
patients (34 on FDCT, 36 on
once daily multipill regimen,
29 on twice daily regimen).
Adherence was
measured via a 30-day
VAS scale.
No significant difference in adherence
was seen between the FDCT and LDCT
once-daily dosed group (p = 0.34).
Airoldi et al. [87], 2010, Italy
Prospective cohort study
To check if there is a link between
a reduction in pill burden and
adherence in HIV patients
6 medical centers in Italy
Follow-up period: 6 months
212 HIV patients who switched
from multipill to
single-pill therapy.
Adherence was
measured via VAS.
Adherence increased clinically
meaningfully for 1.1% (p = 0.01).
Pharmaceutics 2020, 12, 190 40 of 55
Table A2. Cont.
Author, Reference, Year of
Publication, Study Country,
Study Design
Study Aim, Study Setting and
Follow-Up Period Study Population Outcome Measures Main Results (Concerning Adherence)
Bangsberg et al. [30], 2010, USA
Prospective cohort study
To check the influence of a decreased
pill burden on adherence in
HIV therapy
Data obtained via the REACH (The
Research on Access to Care in the
Homeless) cohort
Follow-up period: 6 months
118 HIV patients (47 on
single-pill therapy, 57 and 14 on
different multipill
therapies, respectively).
Adherence was
measured via
unannounced
pill-count.
Adherence was significantly greater for
polypills than for multiple pill users
(p = 0.006).
Santoleri et al. [92], 2018, Italy
Retrospective cohort study
To compare adherence between
patients receiving single or multiple
tablet regimen antiretroviral therapy
Hospital Pharmacy of “Santo Spirito”
Hospital of Pescara, Italy
Follow-up period: 5 years
290 patients who had
withdrawn from taking
antiretroviral drugs for at least
6 months in the 5-year period
(66 on single pill and 227 on
multipill (2, 3, 4, or 5 pills daily)
therapy).
Adherence was
measured via
RDD/PDD ratio.
Single pill therapy group had excellent
adherence value of 0.98, whereas
multiple pill therapy groups had lower
adherence levels of 0.92–0.96 during
years 1–5 of the study.
Yager et al. [94], 2017, USA
Retrospective cohort study
To compare antiretroviral and
non-antiretroviral adherence between
single and multiple tablet regimens
Data retrieved via pharmacy refill
records (Upstate New York Veterans’
Healthcare Administration)
Follow-up period: 1.1 years for
multipill and 2.3 for
single-pill therapy
1202 HIV patients ≥18 years of
age on ≥3 antiretroviral
medications for ≥3 months and
available pharmacy refill
records (165 patients were on
single-pill, 1037 on multiple
tablet regimens).
Adherence was
measured via MPR.
Adherence was significantly higher for
single tablet regimens treatment-naïve
recipients (80.8%–15.4%) compared to the
multipill therapy (65.9%–21.3%),
p < 0.001.
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Sutton et al. [57], 2016, USA
Retrospective cohort study
To evaluate the impact of
antiretroviral therapy as
a single-tablet regimen or
multiple-tablet regimen on outcomes
in HIV patients
Data retrieved via Veterans Health
Administration electronic health
record system
Follow-up period: at least 60 days
15,602 patients to whom HIV
medications were dispensed as
single-tablet (6191 patients) or
multiple-tablet (9411 patients)
during the study period.
Adherence was
measured via MPR.
The odds of adherence were
approximately two times higher in
polypill group than in multiple therapy
group (OR, 2.16; 95% CIs: 1.92–2.43;
p < 0.001).
Sutton et al. [93], 2016, USA
Retrospective cohort study
To assess the impact of pill burden in
HIV patients receiving single-tablet
or multi-tablet regimen on
clinical outcomes
Data retrieved via South Carolina
Medicaid medical and pharmacy
paid claims data
Follow-up period: at least 60 days
2174 patients aged ≥18 years
who were receiving a complete
antiretroviral single-tablet (580
patients) or multiple-tablet
regimen (1594 patients) for at
least 60 days
Adherence was
measured via PDC.
Adherence was higher in single-pill than
in multiple-pill group (80% vs. 67%,
p < 0.0001).
Raffi et al. [47], 2015, France
Retrospective cohort study
To compare adherence and
persistence in HIV adult patients
receiving combination ART (cART) as
a once-daily single-tablet regimen
versus other administration schedules
Data retrieved via French National
Healthcare Insurance Database
Follow-up period: mean 32.8 months
362 patients ≥18 years of age
receiving cART reimbursed in
selection years (76 on
single-tablet regimen, 242
taking >1 pill once daily, 248
having >1 daily intake).
Adherence was
measured via
pill count.
Better adherence was observed with the
polypill in comparison with regimens
with >1 daily intake but no difference
was observed in comparison with
regimens involving >1 pill once daily
(mean adherence 89.6% for the polypill,
86.4% for cART with >1 pill once daily
and 77.0% for cART with >1 daily intake
(p < 0.0001)).
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Tennant et al. [50], 2014, USA
Retrospective cohort study
To compare adherence and virologic
outcomes in adult HIV patients on
single-tablet or multiple-tablet
antiretroviral therapy
Patients enrolled in AIDS Drug
Assistance Program at two
independent clinics in South Carolina
and Alabama
Follow-up period: mean 22 months
(multipill group) and 14 months
(single-pill group)
389 HIV patients aged ≥18 years
with a documented visit to one
of the two clinics and prescribed
one of the two examined
antiretroviral therapy regimens
(165 in single-tablet and 224 on
multipill therapy).
Adherence was
assessed via MPR and
self-reporting.
Median adherence rates were similar in
both groups, regardless of the way it was
assessed (based on clinic records: 91%
and 93% (p < 0.14) in single-pill and
multipill group, respectively;
self-reporting: 100% and 99% (p < 0.05) in
single-pill and multipill group,
respectively). However, the proportion of
adherent patients was higher in
single-pill therapy group; 61.6% vs.
51.5% (p = 0.047; based on clinic records)
and 92.8% vs. 85.4% (p = 0.0179; based on
self-reporting).
Cohen et al. [37], 2013, USA
Retrospective cohort study
To compare adherence, healthcare
utilization and costs in antiretroviral
therapy with once-daily single-tablet
regimen to the therapy with two or
more pills per day
Data retrieved from the MarketScan
Medicaid Multi-State Database
Follow-up period: at least 60 days
7381 patients (5584 taking two
or more pills per day and 1797
on a single-pill therapy) with
an HIV diagnosis receiving
complete antiretroviral therapy.
Adherence was
measured via MPR.
Patients on single-tablet regimens were
significantly more likely to reach 95%
adherence (p < 0.01).
Legoretta et al. [89], 2005, USA
Retrospective cohort study
To investigate the influence of
pill-burden on adherence in
HIV-positive patients
Data obtained via 2 databases, West
Coast and Southeast state Medicaid
Follow-up period: at least 2 months
1427 HIV patients ≥18 years of
age, who were newly started on
antiretroviral therapy and had
at least one prescription refill in
the first 60 postindex days (1363
on polypill therapy, 64 on
multipill therapy).
Adherence was
measured via MPR.
Mean adherence was 85% for polypills,
while it was significantly lower (75%) for
multiple pills therapy (p < 0.001).
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LUTS/BHP (n = 1)
Drake et al. [95], 2017,
the Netherlands
Retrospective cohort study
To compare treatment persistence and
adherence with α-blocker plus
antimuscarinic combination therapy
in men with LUTS/BPH between
those prescribed an FDC and those on
multipill therapy
Data retrieved via the Netherlands
IMS LifeLink™ LRx database, which
contains data from pharmacies and
dispensing (general practices) in
the Netherlands
Follow-up period: 12 months
1891 patients ≥45 years of age,
who received combination
therapy with study drugs as
FDC or multipill therapy (665
on FDC therapy and 1,226 on
multipill therapy).
Adherence was
measured via MPR.
Adherence was similar in both groups of
patients; 80.0% of the patients on FDC
therapy were adherent, while the
adherence among patients on α-blocker
and antimuscarinic concomitant therapy
was 85.8% and 75.2%, respectively
(p = NA).
FDCT, fixed-dose combination therapy; LDCT, loose-dose combination therapy; FDC, fixed-dose combination; LDC, loose-dose combination; SPC, single-pill combination; MT, monotherapy;
MPR, medication possession ratio; RDD/PDD, received daily dose/prescribed daily dose; PDC, proportion of days covered; VAS, visual analog scale; ICD, international classification of
diseases; CVD, cardiovascular disease; DMII, diabetes mellitus type II; HIV, human immunodeficiency virus; HT, hypertension; LUTS/BPH, lower urinary tract symptoms associated with
benign prostatic hyperplasia; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor type I; ARB, angiotensin receptor II blocker; ART, antiretroviral therapy;
CI, confidence interval; OR, odds ratio; NA, not available.
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Table A3. General article information regarding disease, drugs, formulation, and outcomes.
Condition, Reference Active Ingredients in the Polypill andFree-Pill Combination Dose (mg)
Outcome on Adherence
(+: Improved with Using FDC;
−: Decreased with Using FDC;
0: No Difference)
CVD [35] FPC and FDC: acetylsalicylicacid/simvastatin/ramipril 100 mg/40 mg/2.5 mg or 100 mg/40 mg/5 mg or 100 mg/40 mg/10 mg +
CVD [59] FPC and FDC:aspirin/simvastatin/lisinopril/HCTZ 75 mg/40 mg/10 mg/12.5 mg +
CVD [45]
FPC: various; FDC:
aspirin/simvastatin/lisinopril/either
atenolol or HCTZ
75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) +
CVD [48]
FPC: various; FDC:
aspirin/simvastatin/lisinopril with either
atenolol or HCTZ
75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) +
CVD [52]
FPC: various; FDC:
aspirin/simvastatin/lisinopril and either
atenolol or HCTZ
75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) +
CVD [61] FPC and FDC: amlodipine/atorvastatin
FPCs: amlodipine 5 and 10 mg; atorvastatin 10, 20, 40, and 80 mg;
FDCs 5 mg/10 mg or 5 mg/20 mg or 5 mg/40 mg or 5 mg/80 mg or
10 mg/10 mg or 10 mg/20 mg or 10 mg/40 mg or 10 mg/80 mg
+ or −
Hyperlipidemia [58] FPC and FDC: ezetimibe/statin 10 mg/ varying dose (statin) 0
Dyslipidemia [63]
FPC: simvastatin + ezetimibe or
simvastatin + niacin or lovastatin + niacin);
FDC: simvastatin/ ezetimibe or
simvastatin/ niacin or lovastatin/ niacin
Not mentioned +
CVD [62]
FPC: niacin extended-release + lovastatin
or simvastatin; FDC: niacin
extended-release/ lovastatin
Not mentioned +
Dyslipidemia [60] FPC and FDC: niacin/statin Not mentioned +
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CVD [49] FPC: CCB + ACEi; FDC: amlodipinebesylate/benazepril hydrochloride Not mentioned +
HT [75] FPC: ARB + thiazide; FDC: losartan/HCTZ FPC: not mentioned; FDC: 50 mg/12.5 mg 0
HT [66] FPC: various; FDC:olmesartan/amlodipine/HCTZ
20 mg/5 mg/12,5 mg or 40 mg/5 mg/12,5 mg or 40 mg/5 mg/25 mg
or 40 mg/10 mg/12,5 mg or 40 mg/10 mg/25 mg +
HT [73] FPC and FDC: candesartan or valsartan ortelmisartan/amlodipine
ARB (8 mg candesartan or 80 mg valsartan or 40 mg telmisartan)/
5 mg amlodipine +
HT [64] FPC and FDC: ARB/thiazide diuretic orARB/CCB Not mentioned +
HT [67] FPC and FDC: ramipril/amlodipine orcandesartan/amlodipine Not mentioned +
HT [69] FPC and FDC: perindopril/amlodipine Not mentioned +
HT [71] FPC and FDC: RASinhibitor/thiazide diuretic Not mentioned +
HT [77] FPC and FDC: variousantihypertensive medicines Not mentioned +
HT [79] FPC and FDC: ACEi orARB/thiazide diuretic Not mentioned +
HT [74] FPC and FDC: variousantihypertensive medications Not mentioned +
HT [53] FPC and FDC: ARB/dihydropyridine CCB Not mentioned +
HT [42] FPC and FDC: olmesartan/amlodipine 20 mg/5 mg or 40 mg/5 mg or 40 mg/10 mg +
HT [76] FPC and FDC: variousantihypertensive drugs Not mentioned 0
HT [5] FPC and FDC: ARB/thiazide diuretic Not mentioned +
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HT [82]
FPC: amlodipine + valsartan +
hydrocholorothiazide; FDC:
amlodipine/valsartan/HCTZ
Not mentioned +
HT [70] FPC and FDC: olmesartan/ amlodipine Not mentioned +
HT [78] FPC: ARB + CCB; FDC:amlodipine/valsartan Not mentioned +
HT [80] FPC and FDC: thiazide diuretic/eitherACEi or ARB Not mentioned + or −
HT [81] FPC and FDC: olmesartan orvalsartan/HCTZ/amlodipine Not mentioned +
HT [83]
FPC: ARB or ACEi or BB + amlodipine +
hydrocholorthiazide; FDC: BB/HCTZ +
amlodipine or amlodipine/ARB + HCTZ or
ARB/HCTZ + amlodipine or
amlodipine/ACEi + HCTZ or ACEi/HCTZ
+ amlodipine
Not mentioned +
HT [65] FPC: ARB + CCB; FDC:valsartan/amlodipine Not mentioned +
HT [72] FPC: CCB + statin; FDC:amlodipine/atorvastatin Not mentioned +
HT [55]
FPC: ARB + CCB or ARB + HCTZ, or
ACEi + HCTZ; FDC: ARB/CCB or
ARB/HCTZ, or ACEi/HCTZ
Not mentioned +
HT [56]
FPC: ARB + dihydropyridine CCB; FDC:
valsartan/amlodipine or
amlodipine/olmesartan medoxomil
Not mentioned +
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HT [68] FPC: amlodipine + another statin; FDC:amlodipine/ atorvastatin Not mentioned +
HT [41] FPC and FDC: ARB/HCTZ or ACE-I/HCTZor ACEi/CCB Not mentioned +
HT [33] FPC and FDC: valsartan/HCTZ Not mentioned +
HT [39] FPC: CCB + ACEi; FDC:amlodipine/benazepril Not mentioned +
HT [38] FPC: CCB + ACEi; FDC: amlodipinebesylate/benazepril hydrochloride Not mentioned +
HT [46]
FPC and FDC: amlodipine/atorvastatin or
amlodipine/statin or atorvastatin/CCB or
CCB/ statin
Not mentioned +
HT [40] FPC: CCB + ACEi; FDC:amlodipine/benazepril Not mentioned +
DMII [85] FPC and FDC: vildagliptin/metformin FPC: 50 mg vildagliptin + 850 mg metformin; FDC: not mentioned +
DMII [86] FPC and FDC: various oralantidiabetic drugs Not mentioned +
DMII [84] FPC and FDC: various oral antidiabetics Not mentioned +
DMII [31] FPC and FDC: pioglitazone/metformin Not mentioned +
DMII [51] FPC: thiazolidinedione + sulfonurea; FDC:rosiglitazone/glimepiride Not mentioned +
DMII [36] FPC and FDC: any 2 oral antidiabetic drugs(metformin/glyburide/rosiglitazone . . . ) Any market-available dose could be included. +
DMII [44] FPC and FDC: metformin/sulfonylurea Not mentioned +
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Table A3. Cont.
Condition, Reference Active Ingredients in the Polypill andFree-Pill Combination Dose (mg)
Outcome on Adherence
(+: Improved with Using FDC;
−: Decreased with Using FDC;
0: No Difference)
DMII [54] FPC and FDC:metformin/thiazolidinedione
2 mg/1000 mg or 4 mg/1000 mg or 1 mg/500 mg or 2 mg/500 mg or
4 mg/500 mg +
DMII [32] FPC and FDC: glyburide/metformin glyburide from 6 to 10 mg/day/ metformin from 893 mg to1297 mg/day +
DMII [43] FPC and FDC: metformin/glyburide Not mentioned + or 0
HIV [88]
FPC: lopinavir/ritonavir +
zidovudine/lamivudine; FDC:
zidovudine/lamivudine/abacavir
Induction phase: 150 mg lamivudine/300 mg zidovudine twice
daily, 400 mg lopinavir/100 mg ritonavir twice daily. Test phase:
group 2 kept the same regimen, group 1 switched to 300 mg
zidovudine/600 mg lamivudine/600 mg abacavir.
+
HIV [90]
FPC: various; FDC:
rilpivirine/emtricitabine/tenofovir
disoproxil fumarate
Not mentioned 0
HIV [91] FPC and FDC: various antiretroviral drugs Not mentioned +
HIV [34] FPC: various; FDC:efavirenz/emtricitabine/tenofovir Not mentioned 0
HIV [87]
FPC: tenofovir + efavirenz + either
emtricitabine or lamivudine; FDC:
emtricitabine/tenofovir/efavirenz
Not mentioned +
HIV [30]
FPC: ritonavir-boosted protease inhibitor +
two NRTIs or NNRTI + two NRTIs; FDC:
efavirenz/emtricibine/tenofovir
Not mentioned +
HIV [92] FPC and FDC: various antiretroviral drugs Not mentioned +
HIV [94] FPC and FDC: various antiretroviral drugs Not mentioned +
HIV [57]
FPC and FDC:
NRTI/NNRTI/PI/CCR5-antagonist/integrase
inhibitor
Not mentioned +
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Table A3. Cont.
Condition, Reference Active Ingredients in the Polypill andFree-Pill Combination Dose (mg)
Outcome on Adherence
(+: Improved with Using FDC;
−: Decreased with Using FDC;
0: No Difference)
HIV [93] FPC and FDC: various antiretroviral drugs Not mentioned +
HIV [47] FPC and FDC: various antiretroviral drugs Not mentioned + or 0
HIV [50]
FPC: protease inhibitor + atazanavir or
ritonavir + emtricitabine/tenofivor;
FDC: efavirenz/emtricitabine/tenofovir
Not mentioned 0
HIV [37] FPC: various antiretroviral drugs;FDC: tenofovir/emtricitabine/efavirenz Not mentioned +
HIV [89] FPC and FDC: lamivudine/zidovudine 150 mg/300 mg +
LUTS/BPH [95] FPC and FDC: α-blocker/antimuscarinic Not mentioned 0
FPC, free-pill combination; FDC, fixed-dose combination; HT, hypertension; CVD, cardiovascular disease; DMII, diabetes mellitus type II; HIV, human immunodeficiency virus; LUTS/BPH,
lower urinary tract symptoms associated with benign prostatic hyperplasia; CCB, calcium channel blocker; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II
blocker; RAS, renin–angiotensin system; HCTZ, hydrochlorothiazide; BB, beta-blocker; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, nonnucleoside/nucleotide
reverse transcriptase inhibitor; PI, protease inhibitor; CCR5, chemokine receptor 5.
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